Pulse nav.journalClub Debates activos Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia | Synapse

February 1, 2020Open Access

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Evolocumab was well tolerated and effectively reduced plasma LDL-C levels in patients with HoFH and severe HeFH over a median of 4.1 years.

Leer artículo completoexternamente

Me gusta

Guardar

Compartir

Ver artículo completo

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Santos et al. (Sat,) studied this question.

synapsesocial.com/papers/69d7d5a6a2a48916bbbee030 https://doi.org/https://doi.org/10.1016/j.jacc.2019.12.020

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia2002 · 483 citations
2Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study2019 · 18 citations
3Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia2017 · 55 citations
4Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study2012 · 740 citations
5Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study2018 · 30 citations